All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

bexagliflozin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
sodium glucose co-transporter inhibitors, phlorizin derivatives	5708	1118567-05-7

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: bexagliflozin brenzavvy EGT0001442 EGT1442 THR1442 THR-1442

Bexagliflozin is an inhibitor of sodium-glucose co-transporter 2 (SGLT2), the transporter responsible for reabsorption of the majority of glucose from the renal glomerular filtrate in the renal proximal tubule. By inhibiting SGLT2, bexagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion. Molecular weight: 464.94 Formula: C24H29ClO7 CLOGP: LIPINSKI: 0 HAC: 7 HDO: 4 TPSA: 108.61 ALOGS: ROTB: 9 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Jan. 20, 2023	FDA	THERACOSBIO LLC

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
MeSH PA	D007004	Hypoglycemic Agents
FDA MoA	N0000187058	Sodium-Glucose Transporter 2 Inhibitors
FDA EPC	N0000187059	Sodium-Glucose Cotransporter 2 Inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Diabetes mellitus type 2	indication	44054006	DOID:9352
Renal dialysis	contraindication	265764009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
20MG	BRENZAVVY	THERACOSBIO	N214373	Jan. 20, 2023	RX	TABLET	ORAL	8106021	Aug. 22, 2028	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
20MG	BRENZAVVY	THERACOSBIO	N214373	Jan. 20, 2023	RX	TABLET	ORAL	8802637	Aug. 22, 2028	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
20MG	BRENZAVVY	THERACOSBIO	N214373	Jan. 20, 2023	RX	TABLET	ORAL	7838499	Jan. 30, 2029	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
20MG	BRENZAVVY	THERACOSBIO	N214373	Jan. 20, 2023	RX	TABLET	ORAL	10533032	July 3, 2031	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
20MG	BRENZAVVY	THERACOSBIO	N214373	Jan. 20, 2023	RX	TABLET	ORAL	Jan. 20, 2028	NEW CHEMICAL ENTITY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Sodium/glucose cotransporter 2	Transporter	P31639	SC5A2_HUMAN	INHIBITOR	IC50	8.70		DRUG LABEL	DRUG LABEL
Sodium/glucose cotransporter 1	Transporter	P13866	SC5A1_HUMAN	INHIBITOR	IC50	5.25		DRUG LABEL

External reference:

ID	Source
CHEMBL1808388	ChEMBL_ID
C000705992	MESH_SUPPLEMENTAL_RECORD_UI
12335	IUPHAR_LIGAND_ID
DB12236	DRUGBANK_ID
019273	NDDF
C4519094	UMLSCUI
10159	INN_ID
25195624	PUBCHEM_CID
2627044	RXNORM
364775	MMSL
41199	MMSL
D10865	KEGG_DRUG
EY00JF42FV	UNII
d09978	MMSL

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
BRENZAVVY	Human Prescription Drug Label	1	82381-2174	TABLET	20 mg	ORAL	NDA	26 sections